synthetic fmt

  1. Michael Harrop

    FMT Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS (Jan 2025, n=793) 4.2% serious adverse events, 79% success rate.

    https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izae291/7979239 Subgroup of this study: PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides...
Back
Top